Panitumumab

Phase 1Completed

1 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Solid Tumors

Conditions

Solid Tumors

Trial Timeline

Mar 1, 2008 → Mar 1, 2015

NCT ID

NCT00658658

About Panitumumab

Panitumumab is a phase 1 stage product being developed by Amgen for Solid Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT00658658. Target conditions include Solid Tumors.

What happened to similar drugs?

5 of 13 similar drugs in Solid Tumors were approved

Approved (5) Terminated (2) Active (8)

✅DurvalumabAstraZenecaApproved

✅ARM A : IV iron + epoietin zeta + ARM B: IV iron + epoietin zeta sequence + ARM C : single epoietin zetaRocheApproved

✅denosumab + pamidronateAmgenApproved

✅Sacituzumab Govitecan-hiyGilead SciencesApproved

✅Binimetinib only treatment + Encorafenib only Treatment + Encorafenib & Binimetinib Treatment + Treatment of Encorafenib & Binimetinib & Ribociclib + Treatment of Encorafenib & Binimetinib & CetuximabPfizerApproved

🔄olanzapine plus fosaprepitant-based triple regimen + placebo plus fosaprepitant-based triple regimenSun PharmaceuticalPhase 3

🔄MEDI4736 (Durvalumab) + MEDI4736 (Durvalumab) + TremelimumabAstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (19)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03311750	Phase 2	Terminated	Mar 26, 2018	May 20, 2021	Advanced Colorectal Cancer
NCT03043950	Pre-clinical	Completed	Jan 25, 2017	Jan 17, 2024	Metastatic Colorectal Cancer
NCT02301962	Approved	UNKNOWN	Jul 28, 2015	Jan 31, 2022	Cancer
NCT01172717	Phase 2	Withdrawn	Jul 1, 2013	Jul 1, 2013	Carcinoid Syndrome
NCT01312493	Phase 2	Withdrawn	Dec 1, 2011	Dec 1, 2018	Head and Neck Cancer
NCT01412957	Phase 3	Completed	Nov 1, 2011	Nov 1, 2016	Metastatic Colorectal Cancer
NCT00984217	Phase 2	Withdrawn	Aug 1, 2011	Aug 1, 2011	Adenoma, Pleomorphic
NCT01296035	Phase 2	Terminated	Feb 1, 2011	Nov 1, 2013	Ovarian Cancer
NCT01305772	Phase 2	Terminated	Jan 1, 2011	May 1, 2012	Squamous Cell Carcinoma of the Head and Neck
NCT01202409	Phase 2	Completed	Nov 2, 2010	Jul 3, 2018	Gastrointestinal Cancer
NCT01175733	Phase 1/2	Completed	Jul 8, 2010	May 1, 2016	Pancreatic Cancer
NCT01128387	Phase 1/2	Terminated	May 1, 2010	Oct 1, 2016	Cancer
NCT01126112	Phase 2	Completed	May 1, 2010	Jul 1, 2014	Colorectal Cancer
NCT00842257	Phase 2	Completed	May 1, 2009	Dec 1, 2011	Colorectal Cancer
NCT00658658	Phase 1	Completed	Mar 1, 2008	Mar 1, 2015	Solid Tumors
NCT00446446	Phase 2	Completed	Oct 30, 2007	Nov 29, 2017	Cancer
NCT00089635	Phase 2	Completed	Aug 1, 2004	Aug 1, 2008	Colorectal Cancer
NCT00083616	Phase 2	Completed	Mar 1, 2004	Dec 1, 2008	Colorectal Cancer
NCT00113763	Phase 3	Completed	Jan 1, 2004	Jun 1, 2009	Colorectal Cancer

Competing Products

20 competing products in Solid Tumors

See all competitors

Product	Company	Stage	Hype Score
ALG.APV-527	Alligator Bioscience AB	Phase 1/2	18
ATOR-1017	Alligator Bioscience AB	Phase 1	19
ATOR-1015	Alligator Bioscience AB	Phase 1	19
mRNA-4359	Moderna	Phase 2	0
mRNA-2752 + Durvalumab	AstraZeneca	Phase 1	29
mRNA-4106	Moderna	Phase 1	0
mRNA-4157 + Pembrolizumab + SoC Treatment	Merck	Phase 1	33
mRNA-2416	Moderna	Phase 2	0
E7050	Eisai	Phase 1	29
AFM24 + Atezolizumab 840 MG in 14 ML Injection	Affimed	Phase 1/2	14
EXS21546	Biotrial	Phase 1/2	14
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)	Syros Pharmaceuticals	Phase 1	11
BBP-398 + sotorasib	BridgeBio Pharma	Phase 1	18
BBP-398 (Formerly known as IACS-15509)	BridgeBio Pharma	Phase 1	18
SON-1010	Sonnet BioTherapeutics	Phase 1	27
SON-1010	Sonnet BioTherapeutics	Phase 1/2	18
RC220 + Doxorubicin (Adriamycin)	Race Oncology	Phase 1	30
BT1718	Bicycle Therapeutics	Phase 1/2	22
NL-201 + Pembrolizumab Injection [Keytruda]	Neurogene	Phase 1	19
ZN-c3 + Carboplatin + Pegylated liposomal doxorubicin + Paclitaxel + Gemcitabine + Bevacizumab	Zentalis Pharmaceuticals	Phase 1	26